Selective Cell Type Targeting Improves Anti-tumor Activity and Safety of Cytokines

Time: 3:30 pm

Details:

• Asher Bio’s cis-targeting platform generates cell type selective immunomodulators
• Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor activity and safety
• CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor activity